Introduction to the Compendium on Early Cardiovascular Disease DOI Open Access
Matthew Nayor, Donald M. Lloyd‐Jones, Ravi V. Shah

и другие.

Circulation Research, Год журнала: 2023, Номер 132(12), С. 1567 - 1569

Опубликована: Июнь 8, 2023

Язык: Английский

A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association DOI Open Access
Chiadi E. Ndumele, Ian J. Neeland, Katherine R. Tuttle

и другие.

Circulation, Год журнала: 2023, Номер 148(20), С. 1636 - 1664

Опубликована: Окт. 9, 2023

A growing appreciation of the pathophysiological interrelatedness metabolic risk factors such as obesity and diabetes, chronic kidney disease, cardiovascular disease has led to conceptualization cardiovascular-kidney-metabolic syndrome. The confluence within syndrome is strongly linked for adverse outcomes. In addition, there are unique management considerations individuals with established coexisting factors, or both. An extensive body literature supports our scientific understanding of, approach to, prevention However, critical gaps in knowledge related terms mechanisms development, heterogeneity clinical phenotypes, interplay between social determinants health biological accurate assessments incidence context competing risks. There also key limitations data supporting care syndrome, particularly early-life prevention, screening interdisciplinary models, optimal strategies lifestyle modification weight loss, targeting emerging cardioprotective kidney-protective therapies, patients both impact systematically assessing addressing health. This statement uses a crosswalk major guidelines, addition review literature, summarize evidence fundamental science, screening,

Язык: Английский

Процитировано

226

New clinical trial design in precision medicine: discovery, development and direction DOI Creative Commons
Xiao-Peng Duan,

Bao‐Dong Qin,

Xiao‐Dong Jiao

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2024, Номер 9(1)

Опубликована: Март 4, 2024

Abstract In the era of precision medicine, it has been increasingly recognized that individuals with a certain disease are complex and different from each other. Due to underestimation significant heterogeneity across participants in traditional “one-size-fits-all” trials, patient-centered trials could provide optimal therapy customization specific biomarkers were developed including basket, umbrella, platform trial designs under master protocol framework. recent years, successive FDA approval indications based on biomarker-guided demonstrated these new clinical ushering tremendous opportunities. Despite rapid increase number current research understanding designs, as compared remains limited. The majority focuses methodologies, there is lack in-depth insight concerning underlying biological logic designs. Therefore, we this comprehensive review discovery development their perspective medicine. Meanwhile, discuss future directions potential design view “Precision Pro”, “Dynamic Precision”, “Intelligent Precision”. This would assist trial-related researchers enhance innovation feasibility by expounding logic, which be essential accelerate progression

Язык: Английский

Процитировано

49

Social Risk Profile and Cardiovascular‐Kidney‐Metabolic Syndrome in US Adults DOI Creative Commons
Jingkuo Li, Lubi Lei, Wei Wang

и другие.

Journal of the American Heart Association, Год журнала: 2024, Номер 13(16)

Опубликована: Авг. 13, 2024

Poor cardiovascular-kidney-metabolic (CKM) health is associated with premature mortality and excess morbidity in the United States. Adverse social conditions have a prominent impact on cardiometabolic diseases during life course. We aim to examine association between risk profile (SRP) CKM multimorbidity among US adults.

Язык: Английский

Процитировано

10

Lactate-induced lactylation and cardiometabolic diseases: From epigenetic regulation to therapeutics DOI

Jie Lin,

Jun Ren

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Год журнала: 2024, Номер 1870(6), С. 167247 - 167247

Опубликована: Май 16, 2024

Язык: Английский

Процитировано

9

Redox regulation: mechanisms, biology and therapeutic targets in diseases DOI Creative Commons
Bowen Li, Hui Ming, Siyuan Qin

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2025, Номер 10(1)

Опубликована: Март 7, 2025

Redox signaling acts as a critical mediator in the dynamic interactions between organisms and their external environment, profoundly influencing both onset progression of various diseases. Under physiological conditions, oxidative free radicals generated by mitochondrial respiratory chain, endoplasmic reticulum, NADPH oxidases can be effectively neutralized NRF2-mediated antioxidant responses. These responses elevate synthesis superoxide dismutase (SOD), catalase, well key molecules like nicotinamide adenine dinucleotide phosphate (NADPH) glutathione (GSH), thereby maintaining cellular redox homeostasis. Disruption this finely tuned equilibrium is closely linked to pathogenesis wide range Recent advances have broadened our understanding molecular mechanisms underpinning dysregulation, highlighting pivotal roles genomic instability, epigenetic modifications, protein degradation, metabolic reprogramming. findings provide foundation for exploring regulation mechanistic basis improving therapeutic strategies. While antioxidant-based therapies shown early promise conditions where stress plays primary pathological role, efficacy diseases characterized complex, multifactorial etiologies remains controversial. A deeper, context-specific signaling, particularly redox-sensitive proteins, designing targeted aimed at re-establishing balance. Emerging small molecule inhibitors that target specific cysteine residues proteins demonstrated promising preclinical outcomes, setting stage forthcoming clinical trials. In review, we summarize current intricate relationship disease also discuss how these insights leveraged optimize strategies practice.

Язык: Английский

Процитировано

1

Epigenetic biomarkers for disease susceptibility and preventative medicine DOI Creative Commons
Michael K. Skinner

Cell Metabolism, Год журнала: 2024, Номер 36(2), С. 263 - 277

Опубликована: Янв. 3, 2024

Язык: Английский

Процитировано

6

Precision public health in the era of genomics and big data DOI
Megan C. Roberts, Kathryn E. Holt, Guilherme Del Fiol

и другие.

Nature Medicine, Год журнала: 2024, Номер 30(7), С. 1865 - 1873

Опубликована: Июль 1, 2024

Язык: Английский

Процитировано

6

Ambient Pm2.5 Exposure, Physical Activity, and Cardiovascular Dysfunction: Analysis of Charls Data and Experimental Study in Mice DOI
Hao Chang,

Kun Pan,

Xi Zhang

и другие.

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0

Provider Lifestyle Counseling Among Adults With Cardiometabolic Disease Diagnosis Differs by Sociodemographic Characteristics and Lifestyle Modification: NHANES 2017-2020 DOI
Osayande Agbonlahor, Abigail Gamble, Caroline Compretta

и другие.

American Journal of Lifestyle Medicine, Год журнала: 2025, Номер unknown

Опубликована: Янв. 28, 2025

Provider lifestyle counseling is important for improving lifestyles and cardiometabolic disease (CMD) prognosis. However, an examination of the relationship between sociodemographic characteristics, modification provider receipt among adults with CMD scarce. The study examined prevalence associations characteristics diagnosis. We used cross-sectional data from 2017-2020 National Health Nutrition Examination Survey (N = 4847). (i.e., advice to control/lose weight, exercise, reduce salt, fat/calories), (yes or no) were assessed. Adjusted odds ratios evaluated using logistic regression models. Among sample CMD, 44.6% received lose 56.1% 36.1% 43.9% fat/calories. Adults who made modifications had higher receiving weight (OR: 1.81), exercise 1.95), salt 2.23) calories 2.66). Age, sex, race/ethnicity, educational attainment, insurance associated counseling. generally suboptimal U.S. lifetime diagnosis differ by modification. control should involve training providers increase

Язык: Английский

Процитировано

0

Cardiometabolic deaths in black and white men: Tracing the risks from early- to mid-adulthood DOI Creative Commons
Rebecca Arden Harris, Sameed Ahmed M. Khatana, Judith A. Long

и другие.

Preventive Medicine Reports, Год журнала: 2025, Номер 51, С. 102997 - 102997

Опубликована: Фев. 7, 2025

This study aimed to estimate and compare cardiometabolic disease (CMD) mortality in U.S. Black White men during the transition from early adulthood middle age. Using 2022 National Vital Statistics System data standard period life table methods, we estimated risk of CMD death hypothetical cohorts age 25 45 years. We cumulative risk, excess mortality, years lost (YLL), proportion deaths due CMD, stratifying by metabolic cardiovascular disease. Of 325,134 aged initial cohort, before was one 63 individuals or 1.58 %. For men, risks were markedly lower. 1,185,384 158 0.63 The also found that 5141 expected 3090 60.10 % relative cohort. Additionally, all among 19.15 rising 6.02 at 38.00 45, compared with 11.10 increasing 4.57 19.79 45. YLL for averaged 6.72 months per person while 2.94 months. investigation shows profound racial disparities mid-adulthood.

Язык: Английский

Процитировано

0